28243093|t|Corneal permeation properties of a charged lipid nanoparticle carrier containing dexamethasone
28243093|a|Drug delivery carriers can maintain effective therapeutic concentrations in the eye. To this end, we developed lipid nanoparticles (L / NPs) in which the surface was modified with positively charged chitosan, which engaged in hydrogen bonding with the phospholipid membrane. We evaluated in vitro corneal permeability and release characteristics, ocular irritation, and drug dynamics of modified and unmodified L / NPs in aqueous humor. The size of L / NPs was uniform and showed a narrow distribution. Corneal permeation was altered by the presence of chitosan and was dependent on particle size; the apparent permeability coefficient of dexamethasone increased by 2.7 and 1.8 times for chitosan - modified and unmodified L / NPs, respectively. In conclusion, a chitosan - modified system could be a promising method for increasing the ocular bioavailability of unmodified L / NPs by enhancing their retention time and permeation into the cornea. These findings provide a theoretical basis for the development of effective drug delivery systems in the treatment of ocular disease.
28243093	0	7	Corneal	T023	C0010031
28243093	8	18	permeation	T070	C0031164
28243093	19	29	properties	T080	C0871161
28243093	35	48	charged lipid	T109	C0023779
28243093	49	61	nanoparticle	T073	C1450054
28243093	62	69	carrier	T122	C0013161
28243093	70	80	containing	T052	C2700400
28243093	81	94	dexamethasone	T109,T121	C0011777
28243093	95	117	Drug delivery carriers	T122	C0013161
28243093	122	130	maintain	T052	C0024501
28243093	131	140	effective	T080	C1280519
28243093	141	152	therapeutic	T169	C0302350
28243093	153	167	concentrations	T081	C1446561
28243093	175	178	eye	T023	C0015392
28243093	196	205	developed	T169	C1527148
28243093	206	211	lipid	T109	C0023779
28243093	212	225	nanoparticles	T073	C1450054
28243093	227	228	L	T109	C0023779
28243093	231	234	NPs	T073	C1450054
28243093	249	256	surface	T082	C0205148
28243093	261	269	modified	T169	C0205245
28243093	275	293	positively charged	T080	C2825490
28243093	294	302	chitosan	T109,T121	C0162969
28243093	310	317	engaged	T169	C1314939
28243093	321	337	hydrogen bonding	T070	C0020276
28243093	347	359	phospholipid	T109,T123	C0031676
28243093	360	368	membrane	T122	C0005479
28243093	383	391	in vitro	T080	C1533691
28243093	392	399	corneal	T023	C0010031
28243093	400	412	permeability	T070	C0031164
28243093	417	424	release	T169	C0391871
28243093	425	440	characteristics	T080	C1521970
28243093	442	448	ocular	T023	C0015392
28243093	449	459	irritation	T033	C1706307
28243093	465	469	drug	T121	C1254351
28243093	470	478	dynamics	T070	C3826426
28243093	482	490	modified	T169	C0392747
28243093	495	505	unmodified	T080	C2346711
28243093	506	507	L	T109	C0023779
28243093	510	513	NPs	T073	C1450054
28243093	517	530	aqueous humor	T031	C0003662
28243093	536	540	size	T082	C0456389
28243093	544	545	L	T109	C0023779
28243093	548	551	NPs	T073	C1450054
28243093	556	563	uniform	T080	C0205375
28243093	568	574	showed	T169	C0870432
28243093	577	583	narrow	T080	C0333164
28243093	584	596	distribution	T082	C0037775
28243093	598	605	Corneal	T023	C0010031
28243093	606	616	permeation	T070	C0031164
28243093	621	628	altered	T169	C0392747
28243093	636	644	presence	T033	C0150312
28243093	648	656	chitosan	T109,T121	C0162969
28243093	665	674	dependent	T080	C1701901
28243093	678	691	particle size	T081	C0030608
28243093	697	705	apparent	T078	C0750489
28243093	706	718	permeability	T070	C0031164
28243093	719	730	coefficient	T081	C1707429
28243093	734	747	dexamethasone	T109,T121	C0011777
28243093	748	757	increased	T081	C0205217
28243093	783	791	chitosan	T109,T121	C0162969
28243093	794	802	modified	T169	C0205245
28243093	807	817	unmodified	T080	C2346711
28243093	818	819	L	T109	C0023779
28243093	822	825	NPs	T073	C1450054
28243093	858	866	chitosan	T109,T121	C0162969
28243093	869	884	modified system	T169	C0205245
28243093	896	905	promising	T080	C0205170
28243093	906	912	method	T170	C0025663
28243093	917	927	increasing	T169	C0442808
28243093	932	938	ocular	T023	C0015392
28243093	939	954	bioavailability	T081	C0005508
28243093	958	968	unmodified	T080	C2346711
28243093	969	970	L	T109	C0023779
28243093	973	976	NPs	T073	C1450054
28243093	980	989	enhancing	T052	C2349975
28243093	996	1005	retention	T169	C0333117
28243093	1006	1010	time	T079	C0040223
28243093	1015	1025	permeation	T070	C0031164
28243093	1035	1041	cornea	T023	C0010031
28243093	1049	1057	findings	T033	C0243095
28243093	1068	1079	theoretical	T078	C0871935
28243093	1080	1085	basis	T169	C1527178
28243093	1094	1105	development	T169	C1527148
28243093	1109	1118	effective	T080	C1280519
28243093	1119	1140	drug delivery systems	T074	C0085104
28243093	1148	1157	treatment	T061	C0087111
28243093	1161	1175	ocular disease	UnknownType	C0544011